Receptor pharmacogenetics: Relevance to CNS syndromes

British Journal of Clinical Pharmacology

Volumn 54, Issue 4, 2002, Pages 344-348

  Shaikh, Sanober ^a   Kerwin, Robert W ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Individualization of treatment; Neurotransmitter receptors; Pharmacogenomics

Indexed keywords

ACETYLCHOLINESTERASE; AMINO ACID; APOLIPOPROTEIN; CENTRAL NERVOUS SYSTEM AGENTS; CHOLINESTERASE INHIBITOR; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; EMONAPRIDE; ENZYME; FLUVOXAMINE; HISTAMINE RECEPTOR; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER RECEPTOR; NICOTINIC RECEPTOR; OLANZAPINE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN TRANSPORTER; VALPROIC ACID;

ALLELE; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; CENTRAL NERVOUS SYSTEM DISEASE; CHOLINERGIC SYSTEM; DNA POLYMORPHISM; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; GENE TARGETING; GENETIC ANALYSIS; GENETIC CODE; GENETIC VARIABILITY; HUMAN; HUMAN GENOME; INHERITANCE; MANIC DEPRESSIVE PSYCHOSIS; NEUROPSYCHOLOGY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; RECEPTOR BINDING; RECEPTOR GENE; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TREATMENT OUTCOME;

CENTRAL NERVOUS SYSTEM DISEASES; CHOLINERGIC FIBERS; GENOME, HUMAN; HUMANS; NEUROTRANSMITTER AGENTS; RECEPTORS, DOPAMINE; RECEPTORS, NEUROTRANSMITTER;

EID: 0036428695     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01679.x     Document Type: Review

References (46)

1. Kalow W. Pharmacogenetics: Heredity and the Response to Drugs. Philadelphia: W.B. Saunders Co., 1962.
2. Gonzalez FJ, Skoda RC, Kimura S, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988;331: 442-446.
3. Sachse C, Brockmoller J, Bauer S, Roots I. Functional signficance of a C/A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47: 445-449.
4. Nebert DW, Dieter MZ. The evolution of drug metabolism. Pharmacology 2000;61: 124-135.
5. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: Possible implications for opiate addiction. Proc Natl Acad Sci U S A 1998;95: 9608-9613.
6. Arranz MJ, Munro J, Sham P, et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophrenia Res 1998;32: 93-99.
7. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998;3: 508-511.
8. Plomin R, Owen MJ, McGuffin P. The genetic basis of complex human behaviors. Science 1994; 264: 1733-1739.
9. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995; 92: 12260-12264.
10. Rigaud AS, Traykov L, Caputoet al. The apolipoprotein E epsilon4 allele and the response to tacrin therapy in Alzheimer's disease. Eur J Neurol 2000;7: 255-258.
11. Mancama D, Arranz MJ, Munro J, Makoff A, Kerwin RW. The histamine 1 and histamine 2 receptor genes- candidates for schizophrenia and clozapine response. Genescreen 2000;1: 29-34.
12. Briggs CA, McKenna DG, Monteggia LM, et al. Gain of function mutation of the alpha7 nicotinic receptor: Distinct pharmacology of the human alpha7V274T variant. Eur J Pharmacol 1999;366: 301-308.
13. Sodhi M, Murray RM. Central and peripheral nervous systems: Future therapies for schizophrenia. Expert Opinion Therapeutic Patents 1997;7: 151-165.
14. Kerwin RW, Osborne S. Antipsychotic drugs. Medicine 2000; 28: 23-25.
15. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999;21: s106-s115.
16. Arranz MJ, Collier DA, Sodhi M, et al. Association between clozapine response and allelic variation in the 5-HT2A receptor gene. Lancet 1995;346: 281-282.
17. Arranz MJ, Collier DA, Munro J, et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neuroscience Lett 1996;217: 177-178.
18. Masellis M, Basile VS, Meltzer HY, et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998;19: 123-132.
19. Sodhi M, Arranz MJ, Curtis D, et al. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 1995;7: 169-172.
20. Arranz MJ, Munro J, Birkett J,et al. Pharmacogenetic prediction of clozapine response. Lancet 2000;355: 1615-1616.
21. Schumacher J, Schulze TG, Wienker TF, et al. Pharmacogenetics of Clozapine response. Lancet 2000;356: 506-507.
22. Makoff AJ, Graham JM, Arranz MJ, et al. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics 2000;10: 43-48.
23. Van Tol HH, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350: 610-614.
24. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW. Limbic selectivity of clozapine. Lancet 1997; 350: 490-491.
25. Shaikh S, Hodgkinson S, Pilowsky L, Van Os J, Collier D, Gill M. Analysis of the conserved Asp (114) residue of the dopamine D2 receptor in schizophrenic patients. Psychiatric Genet 1994;4: 211-214.
26. Suzuki A, Mihara K, Kondo T, et al. The relationship between dopamine D-2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antiagonist, in schizophrenic patients. Pharmacogenetics 2000;10: 335-341.
27. Chen CH, Wei FC, Koong FJ, Hsiao KJ. Association of TaqIA polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997;41: 827-829.
28. Scharfetter J, Chaudhry HR, Hornik K, et al. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients. European Neuropsychopharmacol 1998;10: 17-20.
29. Basile VS, Masellis M, Badri F, et al. Association of the Msc I polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 1999;21: 17-27.
30. Lovlie R, Thara R, Padmavathi R, Steen VM, McCreadie RG. Ser9Gly dopamine D3 receptor polymorphism and spontaneous dyskinesia in never-medicated schizophrenic patients. Mol Psychiatry 2001;6: 7-8.
31. Segman R, Neeman T, Herseco-Levy U, et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999;4: 247-253.
32. Steen VM, Lovlie R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997;2: 139-145.
33. Shaikh S, Collier D, Kerwin RW, et al. Dopamine D4 receptor subtypes and response to clozapine. Lancet 1993;341: 116.
34. Shaikh S, Collier DA, Sham P, et al. Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. Am J Med Genet 1995;60: 541-545.
35. Kaiser R, Konneker M, Henneken M, et al. Dopamine D4 receptor 48-bp repeat polymorphisms: No association with response to antipsychotic treatment, but association with catatonic schizophrenia. Mol Psychiatry 2000;5: 418-424.
36. Kohn Y, Ebstein RP, Heresco-Levy U, et al. Dopamine D4 receptor gene polymorphisms: Relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. Eur Neuropsychopharmacol 1997;7: 39-43.
37. Rietschel M, Naber D, Oberlander H. et al. Efficacy and side-effects of clozapine: Testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology 1996;15: 491-496.
38. Shaikh S, Makoff A, Collier D, Kerwin R. Dopamine D4 receptors: Potential therapeutic implications in the treatment of schizophrenia. [Review Article.] CNS Drugs 1997; 81: 1-11.
39. Cohen BM, Ennulat DJ, Centorrino F, et al. Polymorphisms of the dopamine D-4 receptor and response to antipsychotic drugs. Psychopharmacology 1999;141: 6-10.
40. Hwu HG, Hong C-J, Lee YL, Lee PC, Lee SFC. Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia. Biol Psychiatry 1998;44: 483-487.
41. Okuyama Y, Ishiguro H, Nankai M, Shibuya H, Watanabe M, Arinami T. Identification of a polymorphism in the promoter region of DRD4 associated with the human novelty seeking personality trait. Mol Psychiatry 2000; 5: 64-69.
42. International Human Genome sequencing consortium. Nature 2001;409: 860.
43. Venter C, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001;291: 1145-1434.
44. Williams M, Coyle JT, Shaikh S, Decker MW. Same brain, new decade: Challenges in cns drug discovery in the postgenomic, proteomic era. Annu Reports Med Chem 2001; 36: 1-10.
45. Collier DA, Stober G, Li T, et al. A novel functional polymorphism within the promoter of the serotonin transporter gene: Possible role in susceptibility to affective disorders. Mol Psychiatry 1996;1: 453-460.
46. Evans WE, Relling MV. Pharmacogenomics translating functional genomics into rational therapeutics. Science 1999; 286: 487-491.